CT引导下射频消融与靶向治疗的对比研究：肺癌患者的干预疗效与生存率

A Comparative Study of CT-Guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients.

作者信息

Zhao Tianyu, Zhang Chunjing, Dai Hang, Li Jingyu, Hao Liguo, Liu Yanan

机构信息

Medical Technology Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.

Foreign Language Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.

出版信息

Curr Med Imaging. 2025 Jan 2. doi: 10.2174/0115734056311827241211092432.

DOI:10.2174/0115734056311827241211092432

PMID:39757653

Abstract

OBJECTIVE

The study aims to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.

METHOD

We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG, n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG, n=40, treated solely with targeted therapy).

RESULTS

The OG group reported 4 cases of Complete Response (CR), 24 cases of Partial Response (PR), 10 cases of Stable Disease (SD), and 2 cases of Progressive Disease (PD). The Overall Response Rate (ORR) was 70.00% (28/40), and the Disease Control Rate (DCR) was 95.00% (38/40). In contrast, the CG group exhibited 3 cases of CR, 20 cases of PR, 12 cases of SD, and 5 cases of PD. The ORR was 57.50% (23/40), and the DCR was 87.50% (35/40). The ORR and DCR in the OG group were significantly higher than those in the CG group. After 6 weeks of treatment, the levels of SCC, CEA, and CA125 in the OG group were significantly lower than those in the CG group; The CD4+ levels in the OG group were significantly higher and the CD8+ levels significantly lower than those in the CG group. A 24-month follow-up showed that the survival rate of the OG group was 47.50% (19/40), which was significantly higher than that of the CG group at 27.50% (11/40).

CONCLUSION

CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.

摘要

目的

本研究旨在评估CT引导下射频消融联合靶向治疗对肺癌患者的临床疗效。

方法

我们回顾性分析了80例肺癌患者。他们被分为观察组（OG，n = 40，接受CT引导下射频消融联合靶向治疗）和对照组（CG，n = 40，仅接受靶向治疗）。

结果

观察组报告完全缓解（CR）4例，部分缓解（PR）24例，疾病稳定（SD）10例，疾病进展（PD）2例。总缓解率（ORR）为70.00%（28/40），疾病控制率（DCR）为95.00%（38/40）。相比之下，对照组有CR 3例，PR 20例，SD 12例，PD 5例。ORR为57.50%（23/40），DCR为87.50%（35/40）。观察组的ORR和DCR显著高于对照组。治疗6周后，观察组的SCC、CEA和CA125水平显著低于对照组；观察组的CD4+水平显著升高，CD8+水平显著低于对照组。24个月的随访显示，观察组的生存率为47.50%（19/40），显著高于对照组的27.50%（11/40）。